Patent · US Active

Antibody-siRNA conjugates and uses therefor

US10278986B2 · kind B2 · utility

0Cited by

21References

20Claims

0Family size

Assignee

The Regents of the University of Colorado, a Body Corporate · US

Inventors

Nirmal Banda · Aurora, US
V. Michael Holers · Denver, US

Key dates

Filing date	Aug 3, 2015
Grant date	May 7, 2019
Priority date	—
Expiry date	Oct 13, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides compositions and methods relating to the treatment of pain, such as pain from rheumatoid arthritis. By creating conjugates of antibodies that target C5aR and siRNA's that target C5 expression, a dual mode therapeutic that targets two different aspects of C5's inflammatory signaling.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.